
- /
- Supported exchanges
- / US
- / OXFYY.PINK
OXFYY (OXFYY PINK) stock market data APIs
OXFYY Financial Data Overview
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows the real-time analysis of DNA or RNA. It offers MinION Mk 1D, a portable device for DNA and RNA; GridION and GridION Q, a compact bench top device, which delivers a version of hardware, software, and chemistry. The company also provides PromethION 2 Solo, PromethION 2, PromethION 24, and PromethION 48. Its platform enables its customers to perform scientific/biomedical research in a various area, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. It operates in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get OXFYY data using free add-ons & libraries
Get OXFYY Fundamental Data
OXFYY Fundamental data includes:
- Net Revenue: 183 M
- EBITDA: -138 628 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
OXFYY News

Oxford Nanopore Technologies Full Year 2024 Earnings: EPS Beats Expectations
Oxford Nanopore Technologies (LON:ONT) Full Year 2024 Results Key Financial Results Revenue: UK£183.2m (up 8.0% from FY 2023). Net loss: UK£146.2m (loss narrowed by 5.4% from FY 2023). UK£0.16 lo...


Aligos Therapeutics Strengthens Board with Two New Independent Directors
Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical comp...

Oxford Nanopore Technologies plc (LON:ONT) is largely controlled by institutional shareholders who own 50% of the company
Key Insights Given the large stake in the stock by institutions, Oxford Nanopore Technologies' stock price might be vulnerable to their trading decisions The top 11 shareholders own 50% of the compan...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.